CMV-CTL for the Treatment of CMV Infection After HSCT
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
Human cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for
recipients of allogeneic hematopoietic stem cell transplantation(HSCT). we propose to study
the immunologic and virologic effects of donor derived CMV specific cytotoxic T lymphocyte
(CMV-CTL) given to transplant recipients
CMV antigen peptides will be used to induce the CMV antigen specific T lymphocytes derived
from donor peripheral blood mononuclear cells for a period of 18~21 days.The patients will
receive CMV-CTL cells when they are sero-positive for CMV-DNA 30 days after transplant. The
CMV-DNA level will be monitored weekly after transfusion.
Phase:
Phase 4
Details
Lead Sponsor:
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Collaborator:
Shanghai iCELL Biotechnology Co., Ltd, Shanghai, China